Safety and Fibrosis Improvement of Grazoprevir and Elbasvir for HCV GT1 and GT6 With or Without HIV

Trial Profile

Safety and Fibrosis Improvement of Grazoprevir and Elbasvir for HCV GT1 and GT6 With or Without HIV

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2018

At a glance

  • Drugs Elbasvir (Primary) ; Elbasvir/grazoprevir (Primary) ; Grazoprevir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Oct 2018 Status changed from not yet recruiting to recruiting.
    • 30 Jul 2018 Planned initiation date changed from 1 Mar 2018 to 1 Aug 2018.
    • 21 Jan 2018 Planned initiation date changed from 1 Nov 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top